Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up

Powles, Thomas; Park, Se Hoon; Caserta, Claudia; Valderrama, Begoña P.; Gurney, Howard; Ullén, Anders; Loriot, Yohann; Sridhar, Srikala S.; Sternberg, Cora N.; Bellmunt, Joaquim; Aragon‐Ching, Jeanny B.; Wang, Jing; Huang, Bo; Laliberte, Robert J; Pietro, Alessandra di; Grivas, Petros

doi:10.1200/jco.22.01792

articleJournal of Clinical OncologyApr 18, 2023HYBRID OA

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up

TPThomas Powles SHSe Hoon Park CCClaudia Caserta BPBegoña P. Valderrama HGHoward Gurney

St Bartholomew's Hospital · Queen Mary University of London · +22 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Initial results from the phase III JAVELIN Bladder 100 trial (ClinicalTrials.gov identifier: NCT02603432 ) showed that avelumab first-line (1L) maintenance plus best supportive care (BSC) significantly prolonged overall survival (OS) and progression-free survival (PFS) versus BSC alone in…

Citation impact

205

total citations

FWCI: 60.65
Percentile: 100%
References: 18

Citations per year

Authors

16

Topics & keywords

Topics

Keywords

Avelumab
Medicine
Clinical endpoint
Metastatic Urothelial Carcinoma
Hazard ratio
Internal medicine
Bladder cancer
Clinical trial

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.